Wexford Capital’s AstraZeneca AZN Stock Holding History

Wexford Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-15,000	Closed	-$1.07M	–	57
2014 Q3	$1.07M	Buy	+15,000	New	+$1.1M	0.1%	79

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wexford Capital's AZN Position: Q2 2025 in Review

Wexford Capital sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 23,176 shares — an estimated $303K sold.

Wexford Capital first reported a position in AZN in Q3 2014 and held it in 19 quarters. The position peaked at $8.45M in Q4 2023. 1,223 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Wexford Capital reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Wexford Capital sold 23,176 AstraZeneca shares in Q2 2025, an estimated $303K.
Wexford Capital first reported a position in AstraZeneca in Q3 2014 and held it in 19 quarters.
Wexford Capital's AstraZeneca position peaked at $8.45M in Q4 2023.
1,223 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.